Both Biofrontera AG (NASDAQ:BFRA) and CRISPR Therapeutics AG (NASDAQ:CRSP) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||52||0.00||34.37M||-3.74||0.00|
Table 1 demonstrates Biofrontera AG and CRISPR Therapeutics AG’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 shows us Biofrontera AG and CRISPR Therapeutics AG’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||66,556,932.61%||-50.9%||-39.8%|
Biofrontera AG and CRISPR Therapeutics AG Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||4||3.00|
Biofrontera AG’s average price target is $18, while its potential upside is 72.91%. On the other hand, CRISPR Therapeutics AG’s potential downside is -3.09% and its average price target is $66.5. The data from earlier shows that analysts opinion suggest that Biofrontera AG seems more appealing than CRISPR Therapeutics AG.
Institutional and Insider Ownership
Biofrontera AG and CRISPR Therapeutics AG has shares owned by institutional investors as follows: 2.04% and 50%. Insiders owned roughly 0.04% of Biofrontera AG’s shares. Competitively, 2% are CRISPR Therapeutics AG’s share owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Biofrontera AG has weaker performance than CRISPR Therapeutics AG
On 6 of the 10 factors Biofrontera AG beats CRISPR Therapeutics AG.
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.